TerminatedPhase 4ketamine

Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease

Sponsored by Children's Hospital of Philadelphia

NCT ID
NCT00252122
Target Enrollment
3 participants
Start Date
2004-06
Est. Completion
2007-01

About This Study

The purpose of this pilot study is to provide a preliminary assessment of the feasibility and efficacy of intravenous ketamine in controlling pain in patients with sickle cell disease (who are admitted to the hospital with severe, acute pain crisis, and who have been resistant to intravenous narcotics).

Conditions Studied

Sickle Cell Disease

Interventions

  • Ketamine

Eligibility

Age:7 Years - 18 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* Children ages 7 to \<19
* Acute vaso-occlusive crisis
* Persistent pain despite initial pain management with intravenous (IV) opioids

Exclusion Criteria:

* Contraindications to the use of ketamine
* Mental retardation or psychological conditions that may affect the proper evaluation of pain and side effects
* Known allergy to ketamine

Study Locations (1)

The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States

This trial is not recruiting

This study is currently not accepting new participants.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source